Description
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), distinguished by a trans-3-hexenoic acid modification at its N-terminus that confers resistance to enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4).
In laboratory research, Tesamorelin is studied for its selective agonism at the GHRHR on pituitary somatotrophs, and is a frequently referenced compound in research examining growth hormone secretion pathways and downstream IGF-1 signaling.
A substantial body of published research has focused on Tesamorelin’s effects on visceral adipose tissue metabolism, making it a reference compound in metabolic and endocrinology research exploring the relationship between the GH axis and fat distribution.
Its structural stability relative to unmodified GHRH allows for more consistent behavior in controlled experimental systems, supporting reproducible study designs.
Researchers use Tesamorelin to investigate structure-activity relationships within the GHRH peptide family and to model interventions targeting the somatotropic axis in metabolic research contexts.
Reviews
There are no reviews yet.